WO1997005195A1 - Method of detecting lung disease - Google Patents
Method of detecting lung disease Download PDFInfo
- Publication number
- WO1997005195A1 WO1997005195A1 PCT/US1996/012377 US9612377W WO9705195A1 WO 1997005195 A1 WO1997005195 A1 WO 1997005195A1 US 9612377 W US9612377 W US 9612377W WO 9705195 A1 WO9705195 A1 WO 9705195A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lung
- acceptable salt
- subject
- pharmaceutically acceptable
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Definitions
- This application concerns lung diagnostic assays in general, and particularly concerns a lung diagnostic assay in which lung mucus secretions are hydrated to facilitate collection thereof.
- sputum samples are particularly important in the treatment and diagnosis of many lung disorders, including lung cancer and tuberculosis (TB) .
- microbial infections of the lung are a serious problem in patients afflicted with acquired immune deficiency syndrome (AIDS) .
- AIDS acquired immune deficiency syndrome
- Two particularly problematic infections are Pneumocystis carinii pneumonia infections and mycobacterial infections.
- PCP Pneumocystis carinii pneumonia infections
- PCP Pneumocystis carinii pneumonia infections
- pentamidine isethionate an unfortunate side effect of this treatment is its toxicity. Accordingly, there is a continued need for techniques which permit the rapid and convenient screening of AIDS patients for this disease, and for the rapid, early, and accurate diagnosis thereof.
- Mycobacteria are a large, diverse, and widely distributed family of aerobic, nonsporulating, nonmotile bacilli that have a high cell-wall lipid content and a slow growth rate. Some Mycobacteria are harmless, while others are significant pathogens.
- the pathogenic Mycobacterium include M. tuberculosis, responsible for tuberculosis, as well as non-tuberculosis Mycobacteria such as M. avium, responsible for ycoJbacterium Avium complex infections.
- a first aspect of the present invention is a method of faciltating the obtaining of a mucus sample from at least one lung of a subject.
- the method comprises administering a physiologically acceptable salt to at least one lung of the subject in an amount effective to hydrate lung mucus secretions therein, and concurrently administering to said at least one lung of the subject, in an amount effective to hydrate lung mucous secretions, and/or stimulate mucus secretions therein, and/or stimulate ciliary beat frequency therein, a compound of Formula (I) below, or a pharmaceutically acceptable salt thereof:
- X l t X 2 , and X 3 are each independently selected from the group consisting of OH and SH;
- R x is selected from the group consisting of 0, imido, methylene, and dihalomethylene;
- R 2 is selected from the group consisting of H and Br.
- the method is accompanied or followed by the step of collecting a mucus sample from said at least one lung of said subject (e.g., by said subject expectorating a sputum sample) .
- Also disclosed is a method of faciltating the obtaining of a mucus sample from at least one lung of a subject comprising administering to at least one lung of said subject, in an amount effective to hydrate lung mucous secretions, and/or stimulate mucus secretions therein, and/or stimulate ciliary beat frequency therein, a compound of Formula (I) as given above, or a pharmaceutically acceptable salt thereof, and then collecting a mucus sample from said at least one lung of said subject.
- the mucus samples collected may then be analyzed for the presence or absence of lung disease (e . g. , microbial infection, cancer, etc.) in said subject.
- a second aspect of the present invention is pharmaceutical composition useful for facilitating the collecting of a mucus sample from at least one lung of a subject, said composition comprising, alone or in combination, a physiologically acceptable salt in an amount effective to hydrate lung mucus secretions; and a compound of Formula (I) as given above, or a pharmaceutically acceptable salt thereof, in an amount effective to hydrate lung mucus secretions.
- the composition may be a liquid composition or a dry powder composition.
- Compounds illustrative of the compounds of Formula (I) above include: (a) uridine 5' -triphosphate (UTP) ; (b) uridine 5' -O- (3-thiotriphosphate) (UTP ⁇ S) ; and (c) 5-bromo- uridine 5' -triphosphate (5-BrUTP) .
- UTP uridine 5' -triphosphate
- UTP ⁇ S uridine 5' -O- (3-thiotriphosphate)
- 5-bromo- uridine 5' -triphosphate 5-BrUTP
- One preferred compound of Formula (I) above is the UTP analog uridine 5'-0-(3- thiotriphosphate) (or "UTP ⁇ S”) .
- UTP Patent Number 5,292,498 to Boucher; N. Cusack and S. Hourani, Annals N. Y. Acad. Sci . 603, 172-181 (G. Dubyak and J. Fedan Eds. 1990) .
- UTP may be made in the manner described in Kenner et al., J. Chem. Soc . 1954, 2288; or Hall and Khorana, J " . Chem. Soc . 76, 5056 (1954) . See Merck Index, Monograph No. 9795 (11th Ed. 1989) .
- UTP ⁇ S may be made in the manner described in R.S. Goody and F. Eckstein, J " . Am. Chem. Soc. 93, 6252 (1971) .
- Formula I herein illustrates uridine triphosphate active compounds in the naturally occurring D configuration, but the present invention also encompasses compounds in the L configuration, and mixtures of compounds in the D and L configurations, unless specified otherwise.
- the naturally occurring D configuration i ⁇ preferred.
- the active compounds of Formula (I) may be administered by themselves or in the form of their pharmaceutically acceptable salts, e.g., an alkali metal salt such as sodium or potassium, an alkaline earth metal salt, or an ammonium and tetraalkyl ammonium salt, NX 4 + (wherein X is a ⁇ alkyl group) .
- pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.
- Amiloride also known as 3, 5, -diamino-6-chloro- N- (diamino ethylene)pyrazinecarboxamide
- benzamil also knownas 3, 5-diamino-6-chloro-N- (benzylaminoaminomethylene) pyrazinecarboxamide
- phenamil also known as 3,5- diamino- 6- chloro -N- (phenylaminoaminomethylene) pyrazinecarboxamide
- amiloride, " “benzamil, “ and “phenamil,” as used herein include the pharmaceutically acceptable salts thereof, such as (but not limited to) amiloride hydrochloride, benzamil hydrochloride or phenamil hydrochloride.
- Amiloride, benzamil or phenamil used to prepare compositions for the present invention may alternatively be in the form of a pharmaceutically acceptable free base of amiloride, benzamil or phenamil. Because the free base of the compound is less soluble than the salt, free base compositions are employed to provide more sustained release of benzamil or phenamil to the lungs.
- Physiologically acceptable salts used to carry out the method of the present invention are those that hydrate lung mucus secretions by facilitating the transport of water from lung endothelial cells into the mucus.
- Physiologically acceptable salts are salts that retain the desired biological activity of hydrating lung mucus secretions and do not impart undesired toxicological effects.
- Physiologically acceptable salts are typically chloride salts, such as sodium chloride, potassium chloride, choline chloride, and N-methyl-D-glucamine chloride. Sodium chloride is currently preferred. These salts may be provided in the form of a dry respirable powder (discussed below) or as an aqueous solution.
- the present invention is concerned primarily with the treatment of human subjects. Subjects may or may not be cystic fibrosis patients. The present invention may also be employed for the treatment of other mammalian subjects, such as dogs and cats, for veterinary purposes.
- the active compounds disclosed herein may be administered to the lung(s) of a subject by any suitable means.
- the word “concurrently” means sufficiently close in time to produce a combined effect (that is, concurrently may be simultaneously, or it may be two or more events occuring within a short time period before or after each other) .
- at least one lung is meant that administration of active compounds may be to one or both lungs of the subject, but where administration is to only one lung, then administration of the various active compounds is to the same lung.
- Active compounds are preferably administered by administering an aerosol suspension of respirable particles comprised of the active compound or active compounds, which the subject inhales.
- the active compound can be aerosolized in a variety of forms, such as, but not limited to, dry powder inhalants, metered dose inhalants, or liquid/liquid suspensions.
- the respirable particles may be liquid or solid.
- the particles may optionally contain other therapeutic ingredients such as amiloride, benzamil or phenamil, with the selected compound included in an amount effective to inhibit the reabsorption of water from airway mucous secretions, as described in U.S. Patent No. 4,501,729 (applicant specifically intends the disclosure of this and all other patent references cited herein be incorporated herein by reference) .
- the particulate pharmaceutical composition may optionally be combined with a carrier to aid in dispersion or transport.
- a suitable carrier such as a sugar (i.e., lactose, sucrose, trehalose, mannitol) may be blended with the active compound or compounds in any suitable ratio (e.g., a 1 to 1 ratio by weight) .
- Particles comprised of active compound for practicing the present invention should include particles . of respirable size: that is, particles of a size sufficiently small to pass through the mouth or nose and larynx upon inhalation and into the bronchi and alveoli of the lungs. In general, particles ranging from about 1 to 10 microns in size (more particularly, less than about 5 microns in size) are respirable. Particles of non- respirable size which are included in the aerosol tend to deposit in the throat and be swallowed, and the quantity of non-respirable particles in the aerosol is preferably minimized. For nasal administration, a particle size in the range of 10-500 ⁇ m is preferred to ensure retention in the nasal cavity.
- Liquid pharmaceutical compositions of active compound for producing an aerosol may be prepared by combining the active compound with a suitable vehicle, such as sterile pyrogen free water.
- a suitable vehicle such as sterile pyrogen free water.
- the hypertonic saline solutions used to carry out the present invention are preferably sterile, pyrogen-free solutions, comprising from one to fifteen percent (by weight) of the physiologically acceptable salt, and more preferably from three to seven percent by weight of the physiologically acceptable salt.
- compounds of Formula (I) or the pharmaceutically acceptable salts thereof are included in the hypertonic saline solution, they are typically included in a concentration ranging from about 10 "4 M to about 10 ⁇ 1 M, and more preferably in a concentration ranging from about 10 "2 M to about 10 "1 M.
- Other therapeutic compounds such as amiloride, benzamil or phenamil may optionally be included
- the saline solution is preferably not more than 0.3 percent by weight of the physiologically acceptable salt, and more preferably is
- Solid particulate compositions containing respirable dry particles of micronized active compound may be prepared by grinding dry active compound with a mortar and pestle, and then passing the micronized composition through a 400 mesh screen to break up or separate out large agglomerates .
- the active compound may be formulated alone (i.e., the solid particulate composition may consist essentially of the active compound) or in combination with a dispersant, diluent or carrier, such as sugars (i.e., lactose, sucrose, trehalose, mannitol) or other acceptable excipients for lung or airway delivery, which may be blended with the active compound in any suitable ratio (e.g., a 1 to 1 ratio by weight) .
- the dry powder solid particulate composition may be obtained by methods known in the art, such as spray-drying, milling, freeze-drying, etc. Again, other therapeutic compounds such as amiloride, benzamil or phenamil may also be included.
- Aerosols of liquid particles comprising the active compound may be produced by any suitable means, such as with a pressure-driven jet nebulizer or an ultrasonic nebulizer. See, e . g. , U.S. Patent No. 4,501,729.
- Nebulizers are commercially available devices which transform solutions or suspensions of the active ingredient into a therapeutic aerosol mist either by means of acceleration of compressed gas, typically air or oxygen, through a narrow venturi orifice or by means of ultrasonic agitation.
- Suitable formulations for use in nebulizers consist of the active ingredient in a liquid carrier, the active ingredient comprising up to 40% w/w of the formulation, but preferably less than 20% w/w.
- the carrier is typically water (and most preferably sterile, pyrogen- free water) or a dilute aqueous alcoholic solution, preferably made isotonic, but may be hypertonic with body fluids by the addition of, for example, sodium chloride.
- Optional additives include preservatives if the formulation is not made sterile, for example, methyl hydroxybenzoate, antioxidants, flavoring agents, volatile oils, buffering agents and surfactants.
- Aerosols of solid particles comprising the active compound may likewise be produced with any solid particulate medicament aerosol generator.
- Aerosol generators for administering solid particulate medicaments to a subject produce particles which are respirable, as explained above, and generate a volume of aerosol containing a predetermined metered dose of a medicament at a rate suitable for human administration.
- One illustrative type of solid particulate aerosol generator is an insufflator.
- Suitable formulations for administration by insufflation include finely comminuted powders which may be delivered by means of an insufflator or taken into the nasal cavity in the manner of a snuff.
- the powder e.g., a metered dose thereof effective to carry out the treatments described herein
- the powder is contained in capsules or cartridges, typically made of gelatin or plastic, which are either pierced or opened in si tu and the powder delivered by air drawn through the device upon inhalation or by means of a manually-operated pump.
- the powder employed in the insufflator consists either solely of the active ingredient or of a powder blend comprising the active ingredient, a suitable powder diluent, such as lactose, and an optional surfactant.
- the active ingredient typically comprises from 0.1 to 100 w/w of the formulation.
- a second type of illustrative aerosol generator comprises a metered dose inhaler.
- Metered dose inhalers are pressurized aerosol dispensers, typically containing a suspension or solution formulation of the active ingredient in a liquified propellant. During use these devices discharge the formulation through a valve adapted to deliver a metered volume, typically from 10 to 200 ⁇ l, to produce a fine particle spray containing the active ingredient .
- Suitable propellants include certain chlorofluorocarbon compounds, for example, dichlorodifluoromethane , trichlorofluoromethane , dichlorotetrafluoroethane and mixtures thereof.
- the formulation may additionally contain one or more co- solvents, for example, ethanol, surfactants, such as oleic acid or sorbitan trioleate, antioxidants and suitable flavoring agents.
- any propellant may be used in carrying out the present invention, including both chlorofluorocarbon- containing propellants and non-chlorofluorocarbon- containing propellants.
- fluorocarbon aerosol propellants that may be employed in carrying out the present invention including fluorocarbon propellants in which all hydrogens are replaced with fluorine, chlorofluorocarbon propellants in which all hydrogens are replaced with chlorine and at least one fluorine, hydrogen- containing fluorocarbon propellants, and hydrogen- containing chlorofluorocarbon propellants.
- propellants include, but are not limited to: CF 3 -CHF- CF 2 H; CF 3 -CH 2 -CF 2 H; CF 3 -CHF-CF 3 ; CF 3 -CH 2 -CF 3 ; CF 3 -CHC1-CF 2 C1; CF 3 -CHC1-CF 3 ; cy-C(CF 2 ) 3 -CHCl; CF 3 -CHCl-CH 2 Cl; CF 3 -CHF-CF 2 C1; CF 3 -CHC1-CFHC1; CF 3 -CFC1-CFHC1; CF 3 -CF 2 -CF 2 H; CF 3 -CF 2 -CH 3 ; CF 2 H-CF 2 -CFH 2 ; CF 3 -CF 2 -CFH 2 ; CF 3 -CF 2 -CFH 2 ; CF 3 -CF 2 -CH 2 Cl; CF 2 H-CF 2 -CH 3 ; CF
- a stabilizer such as a fluoropolymer may optionally be included in formulations of fluorocarbon propellants, such as described in U.S. Patent No. 5,376,359 to Johnson.
- the aerosol may be produced by the aerosol generator at a rate of from about 10 to 150 liters per minute, more preferably from about 30 to 150 liters per minute, and most preferably about 60 liters per minute. Aerosols containing greater amounts of medicament may be administered more rapidly. Typically, each aerosol may be delivered to the patient for a period from about 30 seconds to about 20 minutes, with a delivery period of about five to ten minutes being preferred.
- the dosage of the compound of Formula (I) , or the pharmaceutically acceptable salt thereof will vary depending on the condition being treated and the state of the subject, but generally may be an amount sufficient to achieve dissolved concentrations of active compound on the airway surfaces of the subject of from about IO" 9 to about IO "2 Moles/liter or even 10 "1 Moles/liter, more preferably from about IO "5 to about 10 "1 Moles/liter, and most preferably from about 10 "4 to about IO "3 to about 10” 1 moles/liter.
- the daily dose may be divided among one or several unit dose administrations.
- the sputum sample When the sputum sample is subjected to cytological, bacterial or DNA analysis for detecting infectious microbial species therein, the sputum sample may first be digested with a liquefying agent, such as N- acetyl-L-cystein (NALC) and sodium hydroxide.
- a liquefying agent such as N- acetyl-L-cystein (NALC) and sodium hydroxide.
- the present invention is particularly useful for collecting mucus samples which are used for detecting Pneumocystis carinii pneumonia and Mycobacteria infections.
- Mycobacteria as used herein has its conventional meaning in the art referring to acid-fast, non-motile, rod shaped bacteria. See generally B. Davis et al. , Microbiology, 724-742 (#d. Ed. 1980) . All generally belong to the family Mycobacteriaceae.
- the mycobacteria include, but are not limited to, Mycobacterium africanum, M. avium, M. bovis, M. bovis-BCG, M. chelonae, M. fortui tum, M.
- a subject is caused to inhale an aerosol of UTP solution (10 "2 M UTP in 0.9% (by weight) sterile pyrogen-free saline solution) delivered by a Pari LC Plus nebulizer for 10 minutes.
- the subject is caused to inhale an aerosol of hypertonic saline solution (3% sterile pyrogen-free saline solution) , delivered by a nebulizer for 10 minutes.
- hypertonic saline solution 3% sterile pyrogen-free saline solution
- the subject is encouraged to cough, and all sputum is collected during aerosol inhalation and over a 20 minute interval following cessation of aerosol inhalation.
- the sputum is captured in a plastic sputum container.
- the sputum so obtained is analyzed for content pending the clinical requirement, including analyses of cytologies for pulmonary neoplasm, and the presence of infectious agents, for example, Pneumocystis carinii , by silver staining and immunofluorescence techniques.
- the technique is applicable for the diagnoses of other micro-organisms in the lower lung, including bacterial, viral, amd microplasma, using culture, immunocytochemical, and molecular (PCR, in si tu hybridization) techniques.
- Example 2 is carried out in essentially the same manner as Example 1 above, except that the hypertonic saline solution is delivered first, and the UTP solution is delivered immediately thereafter. Durations of delivery and concentrations remain the same.
- Example 1 above, with 10 "1 UTP being diluted in the hypertonic saline moiston so that a single solution is delivered to the patient by inhalation of an aerosol generated by a nebulizer for a period of 15 minutes.
- Example 1 This procedure is carried out in essentially the same manner as Example 1 above, except that there is no separate administration of a hypertonic saline solution.
- a subject is caused to inhale an aerosol of UTP solution (10 "2 M UTP in 0.9% (by weight) sterile pyrogen-free saline solution) delivered by a Pari LC Plus nebulizer for 10 minutes.
- UTP solution 10 "2 M UTP in 0.9% (by weight) sterile pyrogen-free saline solution
- Pari LC Plus nebulizer During inhalation of the aerosol and after inhalation of the aerosol, the subject is encouraged to cough, and all sputum is collected during aerosol inhalation and over a 20 minute interval following cessation of aerosol inhalation.
- the sputum is captured in a plastic sputum container.
- the sputum so obtained is analyzed as described in Example 1.
- the technique is applicable for the diagnoses of other micro-organisms
- Example 5 This example is carried out in essentially the same manner as Example 5 above, except the subject is administered a respirable dry powder consisting essentially of solid particulate UTP or a pharmaceutically acceptable salt such as trisodium UTP prepared as described above, or as described in U.S. Patent No. 5,292,498 to Boucher.
- a sputum sample is collected from the subject as described in Examples 1 and 5 above, and analyzed as described in Examples 1 and 5 above.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96926158A EP0841900B1 (en) | 1995-07-31 | 1996-07-24 | Pharmaceutical composition for detecting lung disease |
US08/776,772 US6133247A (en) | 1995-07-31 | 1996-07-24 | Method of detecting lung disease |
IL12280396A IL122803A0 (en) | 1995-07-31 | 1996-07-24 | Method fo detecting lung disease |
NZ313864A NZ313864A (en) | 1995-07-31 | 1996-07-24 | Method of obtaining a mucous sample from the lung using triphosphate compounds |
DE69633449T DE69633449T2 (en) | 1995-07-31 | 1996-07-24 | PHARMACEUTICAL COMPOSITION FOR THE DIAGNOSIS OF LUNG DISEASES |
JP50781797A JP3623237B2 (en) | 1995-07-31 | 1996-07-24 | Method for detecting lung disease |
MX9800933A MX9800933A (en) | 1995-07-31 | 1996-07-24 | Method of detecting lung disease. |
AU66399/96A AU705528B2 (en) | 1995-07-31 | 1996-07-24 | Method of detecting lung disease |
BR9610059A BR9610059A (en) | 1995-07-31 | 1996-07-24 | Method to detect lung disease |
AT96926158T ATE276740T1 (en) | 1995-07-31 | 1996-07-24 | PHARMACEUTICAL COMPOSITION FOR DIAGNOSING LUNG DISEASES |
KR1019980700675A KR100283306B1 (en) | 1995-07-31 | 1996-07-24 | Method of detecting lung disease |
NO980279A NO980279D0 (en) | 1995-07-31 | 1998-01-21 | Method for detecting lung disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/509,052 US5628984A (en) | 1995-07-31 | 1995-07-31 | Method of detecting lung disease |
US08/509,052 | 1995-07-31 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/509,052 Continuation-In-Part US5628984A (en) | 1995-07-31 | 1995-07-31 | Method of detecting lung disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/433,757 Continuation US6214536B1 (en) | 1995-07-31 | 1999-11-04 | Method of detecting lung disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997005195A1 true WO1997005195A1 (en) | 1997-02-13 |
Family
ID=24025091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/012377 WO1997005195A1 (en) | 1995-07-31 | 1996-07-24 | Method of detecting lung disease |
Country Status (17)
Country | Link |
---|---|
US (4) | US5628984A (en) |
EP (1) | EP0841900B1 (en) |
JP (2) | JP3623237B2 (en) |
KR (1) | KR100283306B1 (en) |
CN (1) | CN1121441C (en) |
AT (1) | ATE276740T1 (en) |
AU (1) | AU705528B2 (en) |
BR (1) | BR9610059A (en) |
CA (1) | CA2226892A1 (en) |
DE (1) | DE69633449T2 (en) |
ES (1) | ES2229281T3 (en) |
IL (1) | IL122803A0 (en) |
MX (1) | MX9800933A (en) |
NO (1) | NO980279D0 (en) |
NZ (1) | NZ313864A (en) |
WO (1) | WO1997005195A1 (en) |
ZA (1) | ZA966425B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726160A (en) * | 1995-04-13 | 1998-03-10 | Milkhaus Laboratories, Inc. | Methods for treating respiratory disease |
US5948768A (en) * | 1995-04-13 | 1999-09-07 | Milkhaus Laboratory | Treatment of otitis media by sublingual administration of DNA |
US5968913A (en) * | 1996-07-03 | 1999-10-19 | Inspire Pharmaceuticals, Inc. | Pharmaceutical compositions of uridine triphosphate |
US6096721A (en) * | 1995-04-13 | 2000-08-01 | Milkhaus Laboratory, Inc. | Method for treating mucositis by sublingual administration of DNA |
WO2000050024A2 (en) * | 1999-02-26 | 2000-08-31 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
US6998121B2 (en) | 2003-01-23 | 2006-02-14 | Milkhaus Laboratory, Inc. | Method of treatment of connective tissue disorders by administration of streptolysin O |
US7109181B2 (en) | 2001-06-25 | 2006-09-19 | Inspire Pharmaceuticals, Inc. | Joint lubrication with P2Y purinergic receptor agonists |
US7256183B2 (en) | 2001-11-06 | 2007-08-14 | Inspire Pharmaceuticals, Inc. | Method for treating or preventing inflammatory diseases |
US7629312B2 (en) | 2003-01-23 | 2009-12-08 | Milkhaus Laboratory, Inc. | Method of treatment of tendonitis by administration of streptolysin O |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635160A (en) | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
US5763447C1 (en) | 1996-07-23 | 2002-05-07 | Inspire Pharmaceuticals | Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds |
US6159952A (en) * | 1996-11-07 | 2000-12-12 | Inspire Pharmaceuticals, Inc. | Method of treating bronchitis with uridine triphosphate and related compounds |
US6872710B2 (en) * | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
WO1999005155A2 (en) | 1997-07-25 | 1999-02-04 | Inspire Pharmaceuticals, Inc. | Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof |
TW593331B (en) | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
ID29198A (en) * | 1997-08-29 | 2001-08-09 | Univ North Carolina | USE OF URIDIN 5'-DIFOSPHATE AND ITS EQUATION TO TREAT LUNG DISEASE |
NZ512383A (en) * | 1998-12-22 | 2003-05-30 | Univ North Carolina | Use of osmotic agents in the treatment of airway diseases and for the delivery of airway drugs |
US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
JP4969002B2 (en) * | 1999-06-08 | 2012-07-04 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | Compounds and methods for increasing rAAV transduction |
US7241447B1 (en) * | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
US7115585B2 (en) * | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
US7452870B2 (en) * | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
JP3823162B2 (en) * | 2001-07-31 | 2006-09-20 | 株式会社エイアンドティー | Clinical laboratory analyzer, clinical laboratory analysis method, and clinical laboratory analysis program |
US20060196365A1 (en) * | 2001-12-11 | 2006-09-07 | Garman Michael H | Combined water cooler and hot beverage maker |
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
US7435724B2 (en) | 2002-02-27 | 2008-10-14 | Inspire Pharmaceutical, Inc. | Degradation-resistant mononucleoside phosphate compounds |
US20050220720A1 (en) * | 2002-05-02 | 2005-10-06 | David Edwards | Formulations limiting spread of pulmonary infections |
CA2483917C (en) | 2002-05-02 | 2013-07-30 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
AU2004227358B8 (en) * | 2003-03-31 | 2009-12-10 | Targeted Genetics Corporation | Compounds and methods to enhance rAAV transduction |
EP1646371A4 (en) * | 2003-06-26 | 2010-09-22 | Biotron Ltd | Antiviral compounds and methods |
US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
CA2547972A1 (en) * | 2003-11-24 | 2005-06-09 | Georgia State University Research Foundation, Inc. | Fused ring dicationic anti-protozoan agents and their prodrugs |
US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
US20070276020A1 (en) * | 2004-03-08 | 2007-11-29 | Boykin David W | Dicationic Compounds For Activity Against Trichomonas Vaginalis |
US20070099968A1 (en) * | 2004-06-26 | 2007-05-03 | Biotron Limited | Antiviral compounds and methods |
GB0417886D0 (en) * | 2004-08-11 | 2004-09-15 | Univ Cardiff | Method and means for enhanced pulmonary delivery |
WO2006096757A2 (en) * | 2005-03-07 | 2006-09-14 | The University Of North Carolina At Chapel Hill | Inhibitors of reca activities for control of antibiotic-resistant bacterial pathogens |
AU2006201739A1 (en) * | 2005-05-05 | 2006-11-23 | The University Of North Carolina At Chapel Hill | Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles |
EP2402001A1 (en) * | 2005-05-18 | 2012-01-04 | Pulmatrix, Inc. | Formulations for alteration of biophysical properties of mucosal lining |
US8101636B2 (en) * | 2005-06-03 | 2012-01-24 | The University Of North Carolina At Chapel Hill | Linear dicationic terphenyls and their aza analogues as antiparasitic agents |
US7964619B2 (en) | 2005-06-03 | 2011-06-21 | The University Of North Carolina At Chapel Hill | Teraryl components as antiparasitic agents |
US20100249175A1 (en) * | 2005-12-02 | 2010-09-30 | Wilson W David | Dicationic compounds which selectively recognize G-quadruplex DNA |
WO2007127464A2 (en) * | 2006-04-28 | 2007-11-08 | University Of Iowa Research Foundation | Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor |
US20080260863A1 (en) * | 2007-04-20 | 2008-10-23 | Pre Holding, Inc. | Compositions for mucociliary clearance and methods for administering same |
WO2008156783A2 (en) | 2007-06-18 | 2008-12-24 | University Of Louisville Research Foundation, Inc. | Family of pfkfb3 inhibitors with anti-neoplastic activities |
WO2009045536A2 (en) * | 2007-10-05 | 2009-04-09 | The University Of North Carolina At Chapel Hill | Receptor targeted oligonucleotides |
AU2008310734B2 (en) | 2007-10-10 | 2014-06-05 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
US20100331368A1 (en) * | 2007-10-17 | 2010-12-30 | Tidwell Richard R | 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents |
EP2268286B1 (en) | 2008-04-09 | 2016-04-06 | The University of North Carolina At Chapel Hill | Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation |
CN102231983A (en) | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
CA2738925A1 (en) * | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
ES2625260T5 (en) | 2009-03-26 | 2020-07-29 | Pulmatrix Operating Co Inc | Dry powder formulations and methods for the treatment of lung diseases |
CA2761896A1 (en) | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
CA2768154C (en) | 2009-07-13 | 2018-02-13 | Irix Pharmaceuticals | Synthesis of prostanoids |
CA2768582C (en) | 2009-07-24 | 2017-02-14 | University Of Tennessee Research Foundation | Spectinamides as anti-tuberculosis agents |
CA2770565A1 (en) * | 2009-08-10 | 2011-02-17 | P2-Science Aps | Utp for the diagnosis of stenoses and other conditions of restricted blood flow |
WO2011161212A1 (en) * | 2010-06-23 | 2011-12-29 | P2-Science Aps | Combined flow directed intraarterial microcatheter for the infusion of hyperemic agent and concomitant pressure measurements for diagnostic purposes |
US8758824B2 (en) | 2010-08-30 | 2014-06-24 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
CN103200938B (en) | 2010-08-30 | 2018-07-31 | 普马特里克斯营业公司 | Dried powder formula and method for treating pulmonary disease |
CA2812414C (en) | 2010-09-29 | 2020-09-22 | Pulmatrix, Inc. | Monovalent metal cation dry powders for inhalation |
CA2812417C (en) | 2010-09-29 | 2019-10-22 | Pulmatrix, Inc. | Cationic dry powders |
EP2640394A4 (en) | 2010-11-17 | 2015-02-25 | Univ North Carolina | Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6 |
JP6219271B2 (en) | 2011-06-07 | 2017-10-25 | パリオン・サイエンシィズ・インコーポレーテッド | Method of treatment |
US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
AR086745A1 (en) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-DIAMINO-6-CHLORINE-N- (N- (4- (4- (2- (HEXIL (2,3,4,5,6-PENTAHYDROXIHEXIL)) AMINO) ETOXI) PHENYL) BUTIL) CARBAMIMIDOIL) PIRAZINA -2-CARBOXAMIDE |
CN104487075A (en) | 2012-02-29 | 2015-04-01 | 普马特里克斯公司 | Inhalable dry powders |
US9833207B2 (en) | 2012-08-08 | 2017-12-05 | William Harrison Zurn | Analysis and clearing module, system and method |
RU2671976C2 (en) | 2012-12-17 | 2018-11-08 | Пэрион Сайенсиз, Инк. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-2-carboxamide compounds |
PE20151054A1 (en) | 2012-12-17 | 2015-08-07 | Parion Sciences Inc | CHLORINE-PIRAZINE CARBOXAMIDE DERIVATIVES WITH BLOCKING ACTIVITY ON THE EPITHELIAL SODIUM CHANNELS |
US9962533B2 (en) | 2013-02-14 | 2018-05-08 | William Harrison Zurn | Module for treatment of medical conditions; system for making module and methods of making module |
JP6435315B2 (en) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | Highly active antineoplastic and antiproliferative agents |
CN105473140B (en) | 2013-03-15 | 2018-04-10 | G1治疗公司 | To the instantaneous protection of normal cell during chemotherapy |
CN105324106A (en) | 2013-04-01 | 2016-02-10 | 普马特里克斯营业公司 | Tiotropium dry powders |
US10100028B2 (en) | 2013-09-30 | 2018-10-16 | Patheon Api Services Inc. | Synthesis routes for prostaglandins and prostaglandin intermediates using metathesis |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
WO2015161288A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
CN104306028B (en) * | 2014-09-26 | 2016-08-17 | 张清玲 | A kind of sputum collecting method for the detection of respiratory tract bacterial 16 S rRNA gene order |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
US11702672B2 (en) | 2016-02-08 | 2023-07-18 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
MA43735A (en) | 2016-03-07 | 2018-11-28 | Univ Iowa Res Found | AAV MEDIATED EXPRESSION USING SYNTHETIC PROMOTER AND ACTIVATOR |
MX2019000200A (en) | 2016-07-01 | 2019-09-26 | G1 Therapeutics Inc | Pyrimidine-based antiproliferative agents. |
US10413583B2 (en) | 2016-11-30 | 2019-09-17 | The University Of Chicago | Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods |
EP3985002A1 (en) | 2017-03-01 | 2022-04-20 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
GB2604314A (en) * | 2017-09-22 | 2022-09-07 | Nerudia Ltd | Device, system and method |
US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
US11541120B2 (en) | 2017-12-05 | 2023-01-03 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
JP7443375B2 (en) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ, インコーポレーテッド | Macrocyclic compounds for the treatment of medical disorders |
JP2021536511A (en) | 2018-09-06 | 2021-12-27 | アキリオン ファーマシューティカルズ, インコーポレーテッド | Form of Danico bread |
CA3114039A1 (en) | 2018-09-25 | 2020-04-02 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501729A (en) * | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
US5292498A (en) * | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
US5420116A (en) * | 1991-06-05 | 1995-05-30 | Synthelabo | Pharmaceutical compositions for the treatment of disorders of the respiratory tract |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1055465A (en) * | 1962-09-27 | 1967-01-18 | Vantorex Ltd | Allergenic aerosol compositions |
BE639386A (en) * | 1962-10-30 | |||
US4132600A (en) * | 1977-06-01 | 1979-01-02 | Massachusetts Institute Of Technology | Enzymatic noninvasive method for detecting cancer |
FR2571257A1 (en) * | 1984-08-06 | 1986-04-11 | Gros Pierre | Composition for humidifying the rhinopharyngeal mucosa |
US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
US4950477A (en) * | 1988-08-23 | 1990-08-21 | Memorial Hospital For Cancer And Allied Dieseas | Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes |
GB9027968D0 (en) * | 1990-12-22 | 1991-02-13 | Fisons Plc | Method of treatment |
US5567689A (en) * | 1993-08-13 | 1996-10-22 | The Uab Research Foundation | Methods for increasing uridine levels with L-nucleosides |
US5656256A (en) * | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
-
1995
- 1995-07-31 US US08/509,052 patent/US5628984A/en not_active Expired - Lifetime
-
1996
- 1996-07-24 KR KR1019980700675A patent/KR100283306B1/en not_active IP Right Cessation
- 1996-07-24 IL IL12280396A patent/IL122803A0/en unknown
- 1996-07-24 AU AU66399/96A patent/AU705528B2/en not_active Ceased
- 1996-07-24 JP JP50781797A patent/JP3623237B2/en not_active Expired - Fee Related
- 1996-07-24 CN CN96195803A patent/CN1121441C/en not_active Expired - Fee Related
- 1996-07-24 CA CA002226892A patent/CA2226892A1/en not_active Abandoned
- 1996-07-24 EP EP96926158A patent/EP0841900B1/en not_active Expired - Lifetime
- 1996-07-24 WO PCT/US1996/012377 patent/WO1997005195A1/en active IP Right Grant
- 1996-07-24 US US08/776,772 patent/US6133247A/en not_active Expired - Lifetime
- 1996-07-24 BR BR9610059A patent/BR9610059A/en not_active Application Discontinuation
- 1996-07-24 AT AT96926158T patent/ATE276740T1/en not_active IP Right Cessation
- 1996-07-24 MX MX9800933A patent/MX9800933A/en not_active IP Right Cessation
- 1996-07-24 NZ NZ313864A patent/NZ313864A/en unknown
- 1996-07-24 DE DE69633449T patent/DE69633449T2/en not_active Expired - Fee Related
- 1996-07-24 ES ES96926158T patent/ES2229281T3/en not_active Expired - Lifetime
- 1996-07-29 ZA ZA9606425A patent/ZA966425B/en unknown
- 1996-12-30 US US08/777,026 patent/US5902567A/en not_active Expired - Lifetime
-
1998
- 1998-01-21 NO NO980279A patent/NO980279D0/en not_active Application Discontinuation
-
1999
- 1999-11-04 US US09/433,757 patent/US6214536B1/en not_active Expired - Lifetime
-
2002
- 2002-08-05 JP JP2002227140A patent/JP2003073280A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501729A (en) * | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
US5420116A (en) * | 1991-06-05 | 1995-05-30 | Synthelabo | Pharmaceutical compositions for the treatment of disorders of the respiratory tract |
US5292498A (en) * | 1991-06-19 | 1994-03-08 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726160A (en) * | 1995-04-13 | 1998-03-10 | Milkhaus Laboratories, Inc. | Methods for treating respiratory disease |
US5948768A (en) * | 1995-04-13 | 1999-09-07 | Milkhaus Laboratory | Treatment of otitis media by sublingual administration of DNA |
US5955442A (en) * | 1995-04-13 | 1999-09-21 | Milkhaus Laboratory, Inc. | Methods for treating respiratory disease |
US6096721A (en) * | 1995-04-13 | 2000-08-01 | Milkhaus Laboratory, Inc. | Method for treating mucositis by sublingual administration of DNA |
US6100244A (en) * | 1995-04-13 | 2000-08-08 | Milkhaus Laboratory, Inc. | Method for treating respiratory distress by sublingual administration of DNA |
US5968913A (en) * | 1996-07-03 | 1999-10-19 | Inspire Pharmaceuticals, Inc. | Pharmaceutical compositions of uridine triphosphate |
WO2000050024A2 (en) * | 1999-02-26 | 2000-08-31 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
WO2000050024A3 (en) * | 1999-02-26 | 2001-07-05 | Inspire Pharmaceuticals Inc | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
US6331529B1 (en) | 1999-02-26 | 2001-12-18 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
US6436910B1 (en) | 1999-02-26 | 2002-08-20 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
US7109181B2 (en) | 2001-06-25 | 2006-09-19 | Inspire Pharmaceuticals, Inc. | Joint lubrication with P2Y purinergic receptor agonists |
US7256183B2 (en) | 2001-11-06 | 2007-08-14 | Inspire Pharmaceuticals, Inc. | Method for treating or preventing inflammatory diseases |
US6998121B2 (en) | 2003-01-23 | 2006-02-14 | Milkhaus Laboratory, Inc. | Method of treatment of connective tissue disorders by administration of streptolysin O |
US7196058B2 (en) | 2003-01-23 | 2007-03-27 | Milkhaus Laboratory, Inc. | Method of treatment of conditions by administration of streptolysin O |
US7629312B2 (en) | 2003-01-23 | 2009-12-08 | Milkhaus Laboratory, Inc. | Method of treatment of tendonitis by administration of streptolysin O |
Also Published As
Publication number | Publication date |
---|---|
EP0841900A4 (en) | 1998-06-10 |
US6133247A (en) | 2000-10-17 |
BR9610059A (en) | 1999-03-02 |
JP2003073280A (en) | 2003-03-12 |
DE69633449D1 (en) | 2004-10-28 |
CN1191553A (en) | 1998-08-26 |
NO980279L (en) | 1998-01-21 |
ZA966425B (en) | 1997-02-19 |
AU6639996A (en) | 1997-02-26 |
ES2229281T3 (en) | 2005-04-16 |
US6214536B1 (en) | 2001-04-10 |
US5628984A (en) | 1997-05-13 |
EP0841900B1 (en) | 2004-09-22 |
JPH11509759A (en) | 1999-08-31 |
KR100283306B1 (en) | 2001-03-02 |
NO980279D0 (en) | 1998-01-21 |
JP3623237B2 (en) | 2005-02-23 |
IL122803A0 (en) | 1998-09-16 |
MX9800933A (en) | 1998-05-31 |
CN1121441C (en) | 2003-09-17 |
DE69633449T2 (en) | 2006-04-27 |
NZ313864A (en) | 2000-04-28 |
US5902567A (en) | 1999-05-11 |
CA2226892A1 (en) | 1997-02-13 |
KR19990036011A (en) | 1999-05-25 |
EP0841900A1 (en) | 1998-05-20 |
AU705528B2 (en) | 1999-05-27 |
ATE276740T1 (en) | 2004-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0841900B1 (en) | Pharmaceutical composition for detecting lung disease | |
US5849706A (en) | Method of treating retained asthma pulmonary secretions | |
US6387886B1 (en) | Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic | |
EP0941099B1 (en) | Treatment of bronchitis with diuridine tetraphosphate | |
US7851456B2 (en) | P2Y6 receptor agonists for treating lung diseases | |
EP0831777A1 (en) | Dinucleotides useful for the treatment of lung disease | |
CN1143672C (en) | Novel pharmaceutical compositions of uridine triphosphate | |
WO2022047292A1 (en) | Methods for treating newly diagnosed mycobacterium avium complex lung infections | |
MXPA01006134A (en) | Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96195803.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08776772 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AT AU AZ BB BG BR BY CA CH CN CZ CZ DE DE DK DK EE EE ES FI FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 313864 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2226892 Country of ref document: CA Ref document number: 2226892 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996926158 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1997 507817 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980700675 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/1998/000933 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1996926158 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980700675 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019980700675 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996926158 Country of ref document: EP |